179 related articles for article (PubMed ID: 36475459)
1. Opportunities and challenges of neoadjuvant targeted therapy in nonsmall cell lung cancer.
Zou J; Zeng Y; Wu F
Curr Opin Oncol; 2023 Jan; 35(1):22-30. PubMed ID: 36475459
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J; Zhang C; Zhong WZ
Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
[TBL] [Abstract][Full Text] [Related]
3. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
[TBL] [Abstract][Full Text] [Related]
5. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review.
Blakely CM; Weder W; Bubendorf L; He J; Majem M; Shyr Y; Chaft JE
Lung Cancer; 2023 Mar; 177():59-72. PubMed ID: 36736076
[TBL] [Abstract][Full Text] [Related]
6. The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors.
Sun X; Feng Y; Zhang B; Huang W; Zhao X; Zhang H; Yue D; Wang C
Cancer Res Treat; 2022 Oct; 54(4):1017-1029. PubMed ID: 34809413
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
[TBL] [Abstract][Full Text] [Related]
8. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
[TBL] [Abstract][Full Text] [Related]
10. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Therapy in Lung Cancer: What Is Most Important: Objective Response Rate or Major Pathological Response?
Chen X; Ma K
Curr Oncol; 2021 Oct; 28(5):4129-4138. PubMed ID: 34677268
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.
Isaacs J; Stinchcombe TE
Drugs; 2022 Jun; 82(8):855-863. PubMed ID: 35596880
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy in non-small cell lung cancer.
Grant C; Hagopian G; Nagasaka M
Crit Rev Oncol Hematol; 2023 Oct; 190():104080. PubMed ID: 37532102
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
Tieu BH; Sanborn RE; Thomas CR
Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement.
Zhang C; Li SL; Nie Q; Dong S; Shao Y; Yang XN; Wu YL; Yang Y; Zhong WZ
J Thorac Oncol; 2019 Apr; 14(4):726-731. PubMed ID: 30408570
[TBL] [Abstract][Full Text] [Related]
16. Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?
Cai JS; Li S; Yan SM; Yang J; Yang MZ; Xie CL; Li JB; Feng YF; Yang HX; Hou X
Thorac Cancer; 2021 May; 12(9):1336-1346. PubMed ID: 33751832
[TBL] [Abstract][Full Text] [Related]
17. Revisiting neoadjuvant therapy in non-small-cell lung cancer.
Saw SPL; Ong BH; Chua KLM; Takano A; Tan DSW
Lancet Oncol; 2021 Nov; 22(11):e501-e516. PubMed ID: 34735819
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant immunotherapy in nonsmall cell lung cancer.
Pall G
Curr Opin Oncol; 2021 Jan; 33(1):59-63. PubMed ID: 33229874
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
Zhao Z; Gao Y; Xue Q; Gao S; He J
Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
